Latest News
AtaiBeckley reports rapid and durable Phase 2a responses to BPL‑003 in treatment‑resistant depression
...
Solvonis Therapeutics secures second US patent for PTSD compound series
8 April 2026 - Solvonis Therapeutics plc (LSE: SVNS), a biopharmaceutical company developing small-molecule treatments for central nervous system disorders, announced on Wednesday that it has been granted a second US patent (No. 12,595,269) covering ...
GSK secures China approval for Exdensur to treat nasal polyp condition
8 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has received approval from China's National Medical Products Administration for Exdensur (depemokimab) as an add-on treatment for adults with c...
Ondine Biomedical ICU study accepted by Journal of Critical Care
8 April 2026 - Canadian life sciences company Ondine Biomedical Inc (LSE: OBI) reported on Wednesday that a pilot study evaluating its nasal photodisinfection therapy in an intensive care unit setting has been accepted for publication in the Journal ...
Alzinova partners with Amsterdam UMC to advance blood-based Alzheimer's diagnostic
8 April 2026 - Swedish biopharmaceutical company Alzinova AB (Nasdaq First North Growth Market:ALZ) said on Wednesday that it has initiated a research collaboration with Amsterdam University Medical Center (UMC) to develop a blood-based diagnostic te...